Home > Boards > US OTC > Medical - Equipment > Positron Corporation (POSC)

Lantheus indicates the Flurpiridaz F-18 trial timeline has

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
zenvesting Member Profile
 
Followed By 98
Posts 2,843
Boards Moderated 3
Alias Born 02/10/04
160x600 placeholder
zenvesting   Tuesday, 08/04/20 05:19:47 PM
Re: None
Post # of 19426 
Lantheus indicates the Flurpiridaz F-18 trial timeline has been extended due to COVID-19:

https://finance.yahoo.com/news/edited-transcript-lnth-oq-earnings-121431193.html

"Turning now to Flurpiridaz F 18, our novel PET cardiac imaging agent. Our development and commercialization partner, GE Healthcare, has informed us that the second Phase III trial continues. However, new patient enrollment has been delayed due to the impact of the pandemic. GE Healthcare intends to resume enrollment in this quarter and expects to complete enrollment by mid-2021, and, assuming regulatory approval, begin commercialization in early 2023."

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences